Abstract
Multidrug-resistance gene knockout mdr1a/1b(−/−) mice, which are deficient in P-glycoproteins, are more sensitive than wild-type (WT) mice to acute arsenic toxicity. This study assessed toxic manifestations of chronic oral arsenic in mdr1a/1b(−/−) mice, including oxidative stress and altered gene expression, and investigated altered toxicokinetics as a potential basis of enhanced arsenic toxicity. Thus, mdr1a/1b(−/−) and WT mice were exposed to sodium arsenite (0–80 ppm as arsenic) in the drinking water for 10 weeks at which time hepatic arsenic accumulation, lipid peroxidation (LPO), redox status and change in gene expression level were assessed. All mice survived the arsenic exposure, but body weight gain in the highest dose group was reduced in both mdr1a/1b(−/−) and WT mice. Arsenic induced pathological changes, elevated LPO levels and enhanced glutathione S-transferase (GST) activity, in the liver to a greater extent in mdr1a/1b(−/−) than in WT mice. Arsenic also decreased Cu/Zn superoxide dismutase activity in both mdr1a/1b(−/−) and WT mice. The expressions of certain genes, such as those encoding cell proliferation, GST, acute-phase proteins and metabolic enzymes, were modestly altered in arsenic-exposed mice. The expression of cyclin D1, a potential hepatic oncogene, was enhanced in arsenic-exposed mdr1a/1b(−/−) mice only. At the highest level of exposure, hepatic arsenic content was higher in mdr1a/1b(−/−) than in WT mice, suggesting that enhanced accumulation due to transport deficiency may, in part, account for the enhanced toxicity in these mice. In summary, this study shows that chronic arsenic toxicity, including liver pathology and oxidative stress, is enhanced in mdr1a/1b(−/−) mice, possibly due to enhanced accumulation of arsenic as a result of transport system deficiency.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chappell WR, Beck BD, Brown KG, Chaney R, Cothern R, Cothern CR, Irgolic KJ, North DW, Thornton I, Tsongas TA: Inorganic arsenic: A need and an opportunity to improve risk assessment. Environ Health Perspect 105: 1060–1067, 1997
Hughes MF: Arsenic toxicity and potential mechanisms of action. Toxicol Lett 133: 1–16, 2002
Gebel T: Confounding variables in the environmental toxicology of arsenic. Toxicology 144: 155–162, 2000
Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361–398, 1999
Liu J, Chen H, Miller DS, Saavedra JE, Keefer LK, Johnson DR, Klaassen CD, Waalkes MP: Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol 60: 302–309, 2001
Broeks A, Gerrard B, Allikmets R, Dean M, Plasterk RH: Homologues of the human multidrug resistance genes MRP and MDR contribute to heavy metal resistance in the soil nematode Caenorhabditis elegans. Embo J 15: 6132–6143, 1996
Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH: Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 60: 5761–5766, 2000
Liu J, Liu Y, Powell DA, Waalkes MP, Klaassen CD: Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology 170: 55–62, 2002
Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P: Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94: 4028–4033, 1997
Walker NJ: Real-time and quantitative PCR: Applications to mechanism-based toxicology. J Biochem Mol Toxicol 15: 121–127, 2001
Flora SJ: Arsenic-induced oxidative stress and its reversibility following combined administration of N-acetylcysteine and meso 2,3-dimercaptosuccinic acid in rats. Clin Exp Pharmacol Physiol 26: 865–869, 1999
Ramos O, Carrizales L, Yanez L, Mejia J, Batres L, Ortiz D, Diaz-Barriga F: Arsenic increased lipid peroxidation in rat tissues by a mechanism independent of glutathione levels. Environ Health Perspect 103(suppl 1): 85–88, 1995
Pi J, Yamauchi H, Kumagai Y, Sun G, Yoshida T, Aikawa H, Hopenhayn-Rich C, Shimojo N: Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ Health Perspect 110: 331–336, 2002
Li M, Cai JF, Chiu JF: Arsenic induces oxidative stress and activates stress gene expressions in cultured lung epithelial cells. J Cell Biochem 87: 29–38, 2002
Ercal N, Gurer-Orhan H, Aykin-Burns N: Toxic metals and oxidative stress part I: Mechanisms involved in metal-induced oxidative damage. Curr Top Med Chem 1: 529–539, 2001
Vernhet L, Allain N, Bardiau C, Anger JP, Fardel O: Differential sensitivities of MRP1-overexpressing lung tumor cells to cytotoxic metals. Toxicology 142: 127–134, 2000
Kala SV, Neely MW, Kala G, Prater CI, Atwood DW, Rice JS, Lieberman MW: The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem 275: 33404–33408, 2000
Romach EH, Zhao CQ, Del Razo LM, Cebrian ME, Waalkes MP: Studies on the mechanisms of arsenic-induced self tolerance developed in liver epithelial cells through continuous low-level arsenite exposure. Toxicol Sci 54: 500–508, 2000
Gyurasics A, Varga F, Gregus Z: Glutathione-dependent biliary excretion of arsenic. Biochem Pharmacol 42: 465–468, 1991
Gregus Z, Gyurasics A: Role of glutathione in the biliary excretion of the arsenical drugs trimelarsan and melarsoprol. Biochem Pharmacol 59: 1375–1385, 2000
Nordenson I, Beckman L: Is the genotoxic effect of arsenic mediated by oxygen free radicals? Hum Hered 41: 71–73, 1991
Wang TS, Huang H: Active oxygen species are involved in the induction of micronuclei by arsenite in XRS-5 cells. Mutagenesis 9: 253–257, 1994
Chen H, Liu J, Merrick BA, Waalkes MP: Genetic events associated with arsenic-induced malignant transformation: Applications of cDNA microarray technology. Mol Carcinog 30: 79–87, 2001
Rossman TG, Uddin AN, Burns FJ, Bosland MC: Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: An animal model for arsenic carcinogenesis. Toxicol Appl Pharmacol 176: 64–71, 2001
Liu J, Xie Y, Ward JM, Diwan BA, Waalkes MP: Transplacental carcinogenesis of inorganic arsenic in mice: Toxicogenomics analysis. Toxicol Sci (submitted)
Hong F, Zhang A, Huang X: The expression of P16, P21(WAF1/CIP1) and Cyclin D1 proteins in skin of patients with arseniasis caused by coal-burning and their significance. Zhonghua Yu Fang Yi Xue Za Zhi (Chinese J Prev Med) 34: 324–326, 2000 (Chinese)
Chen H, Liu J, Zhao CQ, Diwan BA, Merrick BA, Waalkes MP: Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol Appl Pharmacol 175: 260–268, 2001
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Xie, Y., Liu, J., Liu, Y. et al. Toxicokinetic and genomic analysis of chronic arsenic exposure in multidrug-resistance mdr1a/1b(−/−) double knockout mice. Mol Cell Biochem 255, 11–18 (2004). https://doi.org/10.1023/B:MCBI.0000007256.44450.8c
Issue Date:
DOI: https://doi.org/10.1023/B:MCBI.0000007256.44450.8c